Home Cart Sign in  
Chemical Structure| 845533-86-0 Chemical Structure| 845533-86-0

Structure of Bedaquiline fumarate
CAS No.: 845533-86-0

Chemical Structure| 845533-86-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Bedaquiline fumarate, a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections.

Synonyms: R403323; TMC207 fumarate; TMC-207

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bedaquiline fumarate

CAS No. :845533-86-0
Formula : C36H35BrN2O6
M.W : 671.58
SMILES Code : O[C@](CCN(C)C)(C1=C2C=CC=CC2=CC=C1)[C@@H](C3=CC4=CC(Br)=CC=C4N=C3OC)C5=CC=CC=C5.O=C(O)/C=C/C(O)=O
Synonyms :
R403323; TMC207 fumarate; TMC-207
MDL No. :MFCD28167761
InChI Key :ZLVSPMRFRHMMOY-WWCCMVHESA-N
Pubchem ID :24812732

Safety of Bedaquiline fumarate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mycobacterium avium 0.03 and 16 mg/L Not used Evaluate the in vitro activity of bedaquiline against nontuberculous mycobacteria, results showed that bedaquiline exhibited the highest activity against Mycobacterium avium PMC5404590
Mycobacterium abscessus 0.5 μM (MIC) 48 h To evaluate the effect of bedaquiline on the bactericidal activity of β-lactams. Results showed that bedaquiline dose-dependently reduced the bactericidal activity of β-lactams. PMC6658768
Mycobacterium abscessus 0.5 μM (MIC) 4 h To determine whether β-lactams cause an increase in intrabacterial ATP and assess the inhibitory effect of bedaquiline on this burst. Results showed that β-lactams induced an ATP burst, which was suppressed by bedaquiline. PMC6658768
Mycobacterium tuberculosis H37Rv 0.5–1 µg/mL 14 days To determine the minimum inhibitory concentration (MIC) of bedaquiline against Mycobacterium tuberculosis H37Rv. Results showed the MIC of bedaquiline was 0.5–1 µg/mL. PMC10720489
Mycobacterium kansasii 0.016 μg/ml Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium kansasii. PMC6658790
Mycobacterium abscessus subsp. massiliense 0.062 μg/ml Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium abscessus subsp. massiliense. PMC6658790
Mycobacterium abscessus subsp. abscessus 0.062 μg/ml Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium abscessus subsp. abscessus. PMC6658790
Mycobacterium intracellulare 0.016 μg/ml Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium intracellulare. PMC6658790
Mycobacterium avium 0.016 μg/ml Evaluate the in vitro activity of Bedaquiline against nontuberculous mycobacteria, showing low MIC values for Mycobacterium avium. PMC6658790
Mycobacterium tuberculosis mutant CV37 0.06–0.0038 mg/L 4 weeks To assess the selection advantage of Rv0678 mutants at sub-MIC concentrations, results showed significant enrichment of Rv0678 mutants at sub-MIC concentrations of BDQ and CFZ PMC10989023
Mycobacterium tuberculosis wild-type H37Rv 0.06–0.0038 mg/L 4 weeks To assess the selection advantage of Rv0678 mutants at sub-MIC concentrations, results showed significant enrichment of Rv0678 mutants at sub-MIC concentrations of BDQ and CFZ PMC10989023
Mycobacterium abscessus CIP104536T(S) 0.125 μg/ml 4 days To evaluate the in vitro growth inhibitory effect of bedaquiline on Mycobacterium abscessus, results showed that bedaquiline has a bacteriostatic effect against M. abscessus in vitro. PMC5655087
THP-1 macrophages 20 µg/ml 2 days To evaluate the therapeutic effect of VER and BDQ combination on M. abscessus-infected macrophages, results showed VER significantly enhanced BDQ activity PMC6709475
Mycobacterium abscessus CIP104536T 64 ng/ml 4 days To determine the MIC of BDQ against M. abscessus, results showed VER significantly enhanced BDQ activity PMC6709475

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Subacute tuberculosis infection model Oral 25 mg/kg 5 days per week for 4 weeks To evaluate the bactericidal activity of bedaquiline in combination with pretomanid and linezolid in a mouse model of tuberculosis. Results showed that bedaquiline combined with pretomanid and linezolid significantly reduced lung colony-forming unit (CFU) counts. PMC10720489
BALB/c mice High-dose aerosol infection model of tuberculosis Oral gavage 25 mg/kg Once daily, 5 days per week for 1.5 months Evaluate the bactericidal and sterilizing activity of Bedaquiline combined with pyrazinamide and moxifloxacin. Results showed that the BZM regimen significantly reduced lung CFU counts after 1 month and significantly decreased relapse rates after 1.5 months of treatment. PMC9017355
Zebrafish M. abscessus-infected zebrafish embryo model Water bath administration 1-3 μg/ml Daily change of drug-supplemented water for 3 days To evaluate the therapeutic effect of bedaquiline in a zebrafish model of M. abscessus infection, results showed that bedaquiline significantly increased the survival rate of infected embryos and reduced the formation of abscesses and cords. PMC5655087
C3HeB/FeJ and BALB/c mice Murine tuberculosis model Oral 25 mg/kg 5 times per week for 4 to 8 weeks To evaluate the bactericidal and sterilizing activity of the TBI-166, Bedaquiline, and Pyrazinamide combination regimen in murine tuberculosis models. Results showed that the combination regimen achieved culture-negative lungs after 4 weeks of treatment and no relapse after 8 weeks, with superior bactericidal and sterilizing activity compared to the HRZ regimen and TBI-166+BDQ+LZD regimen. PMC9487531
BALB/c mice Paucibacillary mouse model of latent tuberculosis infection Intramuscular injection 160 mg/kg Monthly for 12 weeks To evaluate the pharmacokinetics and bactericidal activity of a long-acting injectable bedaquiline formulation in a mouse model of latent tuberculosis infection. Results showed that a single dose of bedaquiline exhibited sustained bactericidal activity for at least 12 weeks. PMC6437534

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03625739 - Recruiting December 31, 2026 China ... More >> Beijing Children's Hospital of Capital Medical University Recruiting Beijing, China Contact: Adong Shen, Master    13370115087    shenad16@hotmail.com Less <<
NCT03474198 Tuberculosis, Pulmonary Phase 2 Phase 3 Recruiting March 12, 2022 Philippines ... More >> De La Salle Health Sciences Institute Not yet recruiting Manila, Philippines Lung Center Philippines Recruiting Manila, Philippines Philippines Tuberculosis Society Incorporated (PTSI) Not yet recruiting Manila, Philippines Tropical Disease Foundation Not yet recruiting Manila, Philippines Singapore National University Hospital Not yet recruiting Singapore, Singapore Thailand King Chulalongkorn Memorial Hospital Not yet recruiting Bangkok, Thailand Less <<
NCT00042289 HIV Infections Phase 4 Recruiting September 30, 2019 -
NCT03237182 Tuberculosis, Multidrug-Resist... More >>ant Less << Phase 4 Recruiting December 2021 South Africa ... More >> King Dinuzulu Hospital Recruiting Durban, Kwa-Zulu Natal, South Africa Contact: Nesri Padayatchi, MBcHB    0312604550    nesri.padayatchi@caprisa.org    Contact: Resha Boodhram, BTech    0828383651    resha.boodhram@caprisa.org Less <<
NCT02454205 Tuberculosis ... More >>Multidrug Resistant Tuberculosis Extensively-drug Resistant Tuberculosis Less << Phase 2 Phase 3 Recruiting January 2019 South Africa ... More >> Brooklyn Chest Hospital Recruiting Cape Town, Western Cape, South Africa, 7441 Contact: Ali Esmail, MD    0214047654 ext 6119    a.esmail@uct.ac.za    Contact: Lynelle Mottay, MD    0214046119 ext 6119    lynelle.mottay@uct.ac.za Less <<
NCT02409290 MDR-TB Phase 3 Recruiting December 2021 China ... More >> Beijing Chest Hospital Not yet recruiting Beijing, China Wuhan Institute for TB control Not yet recruiting Wuhan, China Ethiopia Armauer Hanssen Research Institute Recruiting Addis Ababa, Ethiopia St. Peter's Tuberculosis Specializes Hospital Recruiting Addis Ababa, Ethiopia Georgia JSC National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia India BJ Medical College Civil Hospital Recruiting Ahmedabad, India The National Institute for Research in Tuberculosis Recruiting Chennai, India Indonesia RSUP Persahabatan Not yet recruiting Jakarta, Indonesia Moldova, Republic of Institute of Phthisiopneumology 'Chiril Draganiuc' Recruiting Chisinau, Moldova, Republic of Mongolia National Centre for Communicable Diseases Recruiting Ulaanbaatar, Mongolia South Africa King Dinizulu Hospital Recruiting Durban, South Africa Helen Joseph Hospital Recruiting Johannesburg, South Africa Sizwe Tropical Disease Hospital Active, not recruiting Johannesburg, South Africa Doris Goodwin Hospital Recruiting Pietermaritzburg, South Africa Empilweni TB Hospital Not yet recruiting Port Elizabeth, South Africa Uganda Makerere University Recruiting Kampala, Uganda Mulago National Referral Hospital Recruiting Kampala, Uganda Vietnam Pham Ngoc Thach Hospital Active, not recruiting Ho Chi Minh City, Vietnam Less <<
NCT02754765 Tuberculosis, Multidrug-Resist... More >>ant Less << Phase 3 Recruiting April 2021 Georgia ... More >> National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Nino Kiria, MD       msff-tbilisi-endtb@paris.msf.org    Principal Investigator: Nana Kiria, MD          Kazakhstan National Center for Tuberculosis Problems Recruiting Almaty, Kazakhstan Contact: Kanat Khazhidinov, MD       kkhazhidinov@pih.org    Principal Investigator: Elmira Berikova, MD          Kyrgyzstan Osh Oblast Tuberculosis Hospital Not yet recruiting Osh, Kyrgyzstan Contact: Arnol Samiev, MD       msfch-osh-tb@geneva.msf.org    Principal Investigator: Kauk Galina Vladimirovna, MD          Lesotho Partners In Health Lesostho Recruiting Maseru, Lesotho Contact: Sesomo Mohale       smohale@pih.org    Principal Investigator: Lawrence Oyewusi, MBBS          Peru Socios En Salud Recruiting Lima, Peru Contact: Fanny Garcia Velarde       fgarcia_ses@pih.org    Principal Investigator: Leo Lecca, MD          South Africa Medecins Sans Frontieres Belgium Recruiting Khayelitsha, South Africa, 7784 Contact: Jared Borain       msfocb-khayelitsha-endtb@brussels.msf.org    Principal Investigator: Sean Wasserman, MD Less <<
NCT03259269 - Recruiting September 30, 2020 Armenia ... More >> National Treatment Centre for Tuberculosis, Abovian, Armenia Recruiting Abovyan, Armenia Contact: Naira Khachatryan, MD       msff-erevan-medco@paris.msf.org    Principal Investigator: Armen Hayrapetyan, MD          Bangladesh National Institute of Diseases of the Chest and Hospital (NIDCH), Dhaka Recruiting Dhaka, Bangladesh Contact: Hamidah Hussain, MBBS, MSc       hamidah.hussain@irdresearch.org    Contact: Manzur ul-Alam, MD       manzur.ulalam@irdresearch.org    Belarus Republican Research and Practical Centre for Pulmonology and Tuberculosis Recruiting Minsk, Belarus, 220053 Contact: Yoseph Tassew, MD       russia-medco@oca.msf.org    Principal Investigator: Alena Skrahina, MD, PhD, DSc          Ethiopia Bishoftu Hospital Recruiting Bishoftu, Ethiopia Contact: Andargachew Kumsa, MD       AKumsa@pih.org    Georgia National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Tinatin Kotrikadze, MD       msff-tbilisi-medco@paris.msf.org    Principal Investigator: Zara Avaliani, MPH, PhD          Indonesia RS Islam Jakarta Cempaka Putih Not yet recruiting Jakarta, Indonesia Contact: Fauziah Asnely Putri, MD, MPH       fauziah.putri@irdresearch.org    Kazakhstan National Research Center for Phthisionpulmonology Recruiting Almaty, Kazakhstan, 050010 Contact: Yerkebulan Algozhin, MD       ealgozhin@pih.org    Principal Investigator: Elmira Berikova, MPH          Kenya MSF Tuberculosis clinic, Mathare, Nairobi, Kenya Recruiting Nairobi, Kenya Contact: Stephen Wanjala, MD       msff-nairobi-medco@paris.msf.org    Principal Investigator: Maureen Kamene, MD, MBCHB          Kyrgyzstan Kara-Suu District TB hospital Recruiting Kara-Suu, Kyrgyzstan Contact: Hayk Karakozian, MD       MSFCH-Kyrgyzstan-Medco@geneva.msf.org    Principal Investigator: Kadyrov Abdullaat, MD, PhD          Lesotho Botshabelo Hospital Recruiting Maseru, Lesotho Contact: Kwonjune Seung, MD       kjseung@pih.org    Myanmar Aung San Tuberculosis Hospital Not yet recruiting Yangon, Myanmar Contact: Jarmila Kliescikova, MD       myanmar-medco@oca.msf.org    Principal Investigator: Si Tu Aung, MD          Pakistan The Indus Hospital, Karachi Recruiting Karachi, Pakistan Contact: Rabia Mashkoor, MD       rabia.mashkoor@ghd.ihn.org.pk    Principal Investigator: Sana Adnan, MBBS, MSPH          Institute of Chest Diseases, Kotri Recruiting Kotri, Pakistan Contact: Rabia Mashkoor, MD       rabia.mashkoor@ghd.ihn.org.pk    Principal Investigator: Sana Adnan, MBBS, MSPH          Gulab Devi Chest Hospital, Lahore Recruiting Lahore, Pakistan Contact: Rabia Mashkoor, MD       rabia.mashkoor@ghd.ihn.org.pk    Principal Investigator: Sana Adnan, MBBS, MSPH          Peru Socios en Salud Not yet recruiting Carabayllo, Peru Contact: Carmen Contreras, BS       ccontreras_SES@pih.org    Principal Investigator: Leonid Lecca, MD          South Africa King Dinuzulu Hospital Recruiting Durban, South Africa Contact: Munira Khan, MBCHB       munira.khan@irdresearch.org Less <<
NCT01215851 Pulmonary Tuberculosis Phase 2 Completed - South Africa ... More >> Centre for Tuberculosis Research Innovation, UCT Lung Institute Cape Town, South Africa, 7700 Task Applied Science, Karl Bremer Hospital Cape Town, South Africa Less <<
NCT03338621 Tuberculosis, Pulmonary ... More >> Tuberculosis, Multidrug-Resistant Tuberculosis, MDR Tuberculosis Drug-Resistant Tuberculosis Less << Phase 2 Recruiting January 31, 2022 Georgia ... More >> National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Marike Eristavi, MD    +99 559 954 0393    ma.eristavi@gmail.com    Contact: Nestan Tukvadze Less <<
NCT01691534 Pulmonary Tuberculosis Phase 2 Completed - South Africa ... More >> Centre for Tuberculosis Research Innovation, UCT Lung Institute Cape Town, South Africa Task Applied Science, Karl Bremer Hospita Cape Town, South Africa Less <<
NCT01691534 - Completed - -
NCT02589782 Tuberculosis, Multidrug-Resist... More >>ant Extensively Drug-Resistant Tuberculosis Tuberculosis, Pulmonary Less << Phase 2 Phase 3 Recruiting March 2021 Belarus ... More >> Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital Recruiting Minsk, Belarus Contact: Animesh Sinha, MD       minsk-ct-mtl@oca.msf.org    Principal Investigator: Alena Skrahina, MD          South Africa Doris Goodwin Hospital Recruiting Pietermaritzburg, KwaZulu Natal, South Africa Contact: Suzanne Staples       s.staples@thinksa.org.za    Principal Investigator: Ronelle Moodliar, MBBS, MMed          Don McKenzie Hospital Not yet recruiting Durban, KwaZulu-Natal, South Africa Contact: Suzanne Staples       s.staples@thinksa.org.za    Principal Investigator: Ronelle Moodliar, MBBS,MMed          Uzbekistan Republican TB Hospital No. 2 Recruiting Nukus, Karakalpakstan, Uzbekistan Contact: Timur Gilmanov       NukusCT-crc@oca.msf.org    Principal Investigator: Tigay N Zinaida, MD          Sh Alimov Republican Specialised Scientific-Practical Medical Centre for Phthysiology and Pulmonology Hospital Not yet recruiting Tashkent, Uzbekistan Contact: Viktoria Prymaka          Principal Investigator: Irina Liverko, MD Less <<
NCT03086486 Tuberculosis, Pulmonary ... More >> Tuberculosis, Multidrug-Resistant Tuberculosis, MDR Tuberculosis Extensively Drug-Resistant Tuberculosis Pre-XDR-TB Less << Phase 3 Recruiting January 2022 Georgia ... More >> National Center for Tuberculosis and Lung Diseases Recruiting Tbilisi, Georgia, 0101 Contact: Lali Mikiashvili          Principal Investigator: Lali Mikiashvili          Moldova, Republic of Institute of Phthisiopneumology Chiril Draganiuc Not yet recruiting Chisinau, Moldova, Republic of, 2025 Contact: Elena Tudor, MD          Principal Investigator: Elena Tudor, MD          Russian Federation Central TB Research Institute of the Federal Agency of Scientific Organizations Moscow Not yet recruiting Moscow, Russian Federation, 107564 Contact: Tatevik Bagdasaryan          Principal Investigator: Tatevik Bagdasaryan          Research Institute of Phthisiopulmonology of I.M. Sechenov First Moscow State Medical University Not yet recruiting Moscow, Russian Federation Contact: Anastasia Samoilova          Principal Investigator: Anastasia Samoilova          FSBI "Saint-Petersburg Research Institute of Phthisiopulmonology" Recruiting Saint Petersburg, Russian Federation, 191036 Contact: Petr Yablonskiy, MD          Principal Investigator: Petr Yablonskiy, MD          Ural Research Institute of Phthisiopulmonology Not yet recruiting Yekaterinburg, Russian Federation, 620039 Contact: Sergey Skornyakov, MD          Principal Investigator: Sergey Skornyakov, MD          South Africa Tshepong Hospital Recruiting Klerksdorp, North - West, South Africa, 2574 Contact: Ebrahim Variava          Principal Investigator: Ebrahim Variava          King DinuZulu Hospital Complex Recruiting Durban, South Africa, 4015 Contact: Nosipho Ngubane          Principal Investigator: Nosipho Ngubane          Clinical HIV Research Unit (CHRU) Sizwe Tropical Diseases Hospital Recruiting Johannesburg, South Africa, 2131 Contact: Pauline Howell, MD          Principal Investigator: Pauline Howell, MD          Empilweni TB Hospital Not yet recruiting Johannesburg, South Africa, 2194 Contact: Francesca Conradie, MBBS          Principal Investigator: Francesca Conradie, MBBS Less <<
NCT01215851 - Completed - -
NCT01600963 Multi-drug Resistant Tuberculo... More >>sis Less << Phase 3 Withdrawn(PhIII program revise... More >>d; TMC207-C210 cancelled) Less << November 2022 -
NCT00946842 Healthy Phase 1 Completed - -
NCT02193776 Tuberculosis Phase 2 Completed - South Africa ... More >> The Aurum Institute: Tembisa Hospital Tembisa, Gauteng, South Africa, 1632 Klerksdorp Tshepong Hospital Jouberton, Klerksdorp, South Africa, 2570 TASK Applied Science Cape Town, South Africa, 7531 University of Cape Town Lung Institute (Pty) Ltd Cape Town, South Africa, 7937 THINK: Tuberculosis & HIV Investigative Network of KwaZulu-Natal Durban, South Africa CHRU Themba Lethu Clinic Johannesburg, South Africa University of Witwatersrand, Clinical HIV Research Unit (CHRU), Helen Joseph Hospital Johannesburg, South Africa Tanzania Ifakara Health Institute Bagamoyo, Tanzania NIMR-Mbeya Medical Research Centre (MMRC) Mbeya, Tanzania Uganda Uganda Case Western Reserve University Research Collaboration Kampala, Uganda Less <<
NCT00449644 - Completed - -
NCT02583048 Tuberculosis ... More >>HIV Infections Less << Phase 2 Active, not recruiting April 27, 2020 Peru ... More >> Barranco CRS Lima, Peru, 15063 South Africa Task Applied Science (TASK) CRS Cape Town, Western Cape Province, South Africa, 7530 South African Tuberculosis Vaccine Initiative (SATVI) CRS Cape Town, Western Cape Province, South Africa, 7705 Less <<
NCT01464762 - - - Lithuania ... More >> Vilnius, Lithuania Russian Federation Arkhangelsk, Russian Federation Moscow, Russian Federation Orel, Russian Federation Saint-Petersburg, Russian Federation Less <<
NCT00449644 Tuberculosis Phase 2 Completed - Brazil ... More >> Rio De Janeiro, Brazil India Chennai, India New Delhi, India Latvia Stopinu Region, Latvia Peru Lima, Peru Philippines Quezon City, Philippines Russian Federation Moscow, Russian Federation South Africa Bethelsdorp, South Africa Cape Town, South Africa Durban, South Africa George, South Africa Klerksdorp, South Africa Sandringham, South Africa Thailand Chiang Mai, Thailand Nakhon, Thailand Nonthaburi, Thailand Less <<
NCT01341184 Tuberculosis Phase 1 Completed - United States, Ohio ... More >> Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine Cleveland, Ohio, United States, 44106-1716 Less <<
NCT01291563 Healthy Volunteer Phase 1 Completed - -
NCT01215110 Pulmonary Tuberculosis Phase 2 Completed - South Africa ... More >> Karl Bremer Hospital Belville, Cape Town, South Africa, 7531 Less <<
NCT02274389 - Active, not recruiting December 31, 2018 United States, North Carolina ... More >> Raleigh, North Carolina, United States Less <<
NCT00523926 Tuberculosis Phase 2 Completed - -
NCT00992069 Tuberculosis ... More >>HIV Less << Phase 1 Completed - United States, California ... More >> Ucsf Aids Crs San Francisco, California, United States, 94110 United States, Maryland Johns Hopkins Adult AIDS CRS Baltimore, Maryland, United States, 21287 United States, North Carolina Unc Aids Crs Chapel Hill, North Carolina, United States, 27514 United States, Ohio The Ohio State Univ. AIDS CRS Columbus, Ohio, United States, 43210 United States, Tennessee Vanderbilt Therapeutics CRS Nashville, Tennessee, United States, 37232-2582 Less <<
NCT02333799 Pulmonary Tuberculosis Phase 3 Active, not recruiting October 2021 South Africa ... More >> Task Applied Science - Brooklyn Chest Hospital Ysterplaat, Cape Town, South Africa, 7405 King DinuZulu Hospital Complex Sydenham, Durban, South Africa, 4001 Sizwe Tropical Disease Hospital Sandringham, Johannesburg, South Africa, 2131 THINK: Tuberculosis & HIV Investigative Network of KwaZulu-Natal (Durban) Pietermaritzburg, Kwazulu-Natal, South Africa, 3200 Less <<
NCT02906007 Tuberculosis ... More >>HIV Infections Less << Phase 1 Phase 2 Recruiting January 31, 2022 Haiti ... More >> Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS Recruiting Port-au-Prince, Haiti, HT-6110 Contact: Cynthia Riviere, M.D.    509-22222241    criviere@gheskio.org    India Byramjee Jeejeebhoy Medical College (BJMC) CRS Recruiting Pune, Maharashtra, India, 411001 Contact: Nishi Suryavanshi, Ph.D.    91-98-23248979    nishi@jhumitpune.com    South Africa Sizwe CRS Recruiting Johannesburg, Gauteng, South Africa Contact: Katerina Selibas    27-11-8823912    kselibas@witshealth.co.za    PHRU Matlosana CRS Recruiting Klerksdorp, North West Province, South Africa, 2574 Contact: Katlego Motlhaoleng    27-18-4063359    motlhaolengk@phru.co.za    Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS Recruiting Cape Town, Western Cape Province, South Africa, 7505 Contact: Frieda A. Verheye-Dua    27-21-9389772    Frieda@sun.ac.za Less <<
NCT00910806 HIV Infections Phase 1 Completed - South Africa ... More >> George, South Africa Less <<
NCT00828529 Tuberculosis ... More >>HIV Less << Phase 1 Completed - -
NCT00910871 Tuberculosis Phase 2 Completed - -
NCT01012284 Moderate Hepatic Impairment Phase 1 Completed - -
NCT00910871 - Completed - -
NCT03032367 Tuberculosis Early Phase 1 Completed - South Africa ... More >> TASK Clinical Research Centre Bellville, Western Cape, South Africa, 7530 Less <<
NCT02216331 Tuberculosis Phase 1 Completed - United States, Nebraska ... More >> Celerion (MDS Pharma Services) Lincoln, Nebraska, United States, 68502 Less <<
NCT01803373 Healthy Biolo... More >>gical Availability Less << Phase 1 Completed - Netherlands ... More >> Groningen, Netherlands Less <<
NCT02365623 Tuberculosis, Multidrug-Resist... More >>ant Less << Phase 2 Active, not recruiting September 12, 2020 Japan ... More >> Kiyose, Japan Sakai, Japan Less <<
NCT03384641 Leprosy, Multibacillary Phase 2 Recruiting July 7, 2021 Brazil ... More >> Instituto Lauro de Souza Lima Recruiting Bauru, Brazil, 17034-971 Alfredo da Matta Foundation Not yet recruiting Manaus, Brazil, 69065-130 Less <<
NCT02354014 Multidrug-Resistant Tuberculos... More >>is Less << Phase 2 Recruiting July 13, 2025 India ... More >> B. J. Medical College & Civil Hospital Withdrawn Ahmedabad, India, 380 016 National Institute for Research in Tuberculosis (NIRT) Withdrawn Chennai, India, 600 031 National Institute of Tuberculosis and Respiratory Diseases (NITRD) Withdrawn New Delhi, India, 110 030 Philippines De La Salle Health Sciences Institute- DLSUMC Recruiting Dasmarinas, Philippines, 4114 Lung Center Of The Philippines Completed Quezon City, Philippines, 1100 Russian Federation First Moscow State Medical University n.a. I.M. Sechenov Recruiting Moscow, Russian Federation, 119991 South Africa THINK: Tuberculosis & HIV Investigative Network Recruiting Durban, South Africa, 4001 Less <<
NCT01215110 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.49mL

0.30mL

0.15mL

7.45mL

1.49mL

0.74mL

14.89mL

2.98mL

1.49mL

References

 

Historical Records

Categories